X4 Pharmaceuticals
XFOR
91 hedge funds and large institutions have $123M invested in X4 Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 15 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0.09% less ownership
Funds ownership: 2.37% → 2.28% (-0.09%)
4% less funds holding
Funds holding: 95 → 91 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
35% less call options, than puts
Call options by funds: $323K | Put options by funds: $494K
44% less capital invested
Capital invested by funds: $219M → $123M (-$96.5M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$10.9M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$3.12M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.61M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.24M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$972K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$4.46M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$4.31M |
| 3 |
Millennium Management
New York
|
-$2.67M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.85M |
| 5 |
BlackRock
New York
|
-$1.36M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Belvedere Trading
Chicago,
Illinois
| – | -$55.8K | -959 | Closed |
|
102
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$46.2K | -793 | Closed |
|
|
VF
103
Virtu Financial
New York
| – | -$29K | -503 | Closed |
|
|
MWM
104
Mission Wealth Management
Santa Barbara,
California
| – | -$29.1K | -500 | Closed |
|
|
V
105
Veritable
Wilmington,
Delaware
| – | -$24.5K | -421 | Closed |
|
|
IGWM
106
ICA Group Wealth Management
Denver,
Colorado
| – | -$2.62K | -45 | Closed |
|
XFOR Hedge Fund Activity: Q3 2023 in Review
91 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2023, worth a combined $123M — down 44% from $219M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of XFOR and 11 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 27 added.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $10.9M. The largest seller was CVI Holdings, exiting entirely with an estimated $4.46M sold.
- 91 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2023, down from 95 in Q2 2023.
- Funds reported $123M of X4 Pharmaceuticals stock for Q3 2023, down 44% quarter-over-quarter.
- 11 funds opened new X4 Pharmaceuticals positions in Q3 2023 and 15 closed out, a net change of -4 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2023 was Polar Capital Holdings, an estimated $10.9M added.
- The largest X4 Pharmaceuticals seller in Q3 2023 was CVI Holdings, an estimated $4.46M sold.
Based on aggregated 13F filings for Q3 2023.